Due to its precise genome editing capabilities, the prokaryotic CRISPR–Cas system has revolutionized molecular biology – and has potential applications in gene therapy and biotechnology [1]. Nonetheless, recent research has highlighted the need for more compact CRISPR-Cas complexes, which could be delivered to cellular systems more efficiently [2]
The importance of effective adeno-associated virus (AAV) analysis – and how mass photometry can support this – has been recognized in recent publications.
There is no better measure for the success of an analytical technology than its widespread adoption by the people who need the best data! As news of the capabilities and applications of mass photometry spreads, more and more scientists are choosing to use it. In fact, the number of scientific publications relying on mass photometry has grown by an average of 168% per year over the past 6 years. In August 2024, we hit a new milestone: 500 mass photometry papers! For a technology as young as mass photometry, that is truly remarkable.
Refeyn has taken another step to assure mass photometry is a simpler, more efficient bioanalytics tool with the release of a powerful expansion of its consumables portfolio.
Refeyn has established a new Scientific Advisory Board, chaired by Justin Benesch, Professor of Biophysical Chemistry, Oxford University and co-founder of Refeyn. To recognize and help realize the full potential of mass photometry’s unique bioanalytical workflow capabilities, the new board includes external scientific experts in pharmaceutical and biologics discovery, process development and manufacture.
Genetic Engineering & Biotechnology News (GEN) published a short article discussing how researchers at the UK Centre for Process Innovation (CPI) found mass photometry to be a helpful analytical technique for companies using adeno-associated viruses (AAV) as viral vectors in gene therapies.
An article authored by Laura Pala, one of our Product Marketing Managers, has recently been published by Eurolab magazine and also online at ScientistLive. It provides a useful overview of macro mass photometry and how it can help to speed up viral vector characterization, a key analytical step within the production pipeline for cell and gene therapies (CGT) and vaccines.
Refeyn staff join mass photometry inventor Prof. Philip Kukura in cutting ribbon to Refeyn’s new US customer interaction center in Massachusetts’ Waltham Biotech Hub
The remarkable evolution of mass photometry was celebrated at the annual mass photometry user summit. From prototype to commercially available instrument used in hundreds of laboratories, this innovative technology was on display at the third annual scientific meeting of this event – dedicated to mass photometry users and hosted by Refeyn. The event took place at Wylie Conference Center on May 22 in Beverly, Massachusetts, a coastal suburb of Boston, USA.
Refeyn is delighted to announce the appointment of Fiona Coats as Chief Marketing Officer, effective from June, 2024. Forming part of Refeyn’s executive team, Fiona will bring with her a wealth of experience from over 25 years in the biotechnology sector.
ABL, an Institut Mérieux Company, is a distinguished contract development and manufacturing organization (CDMO) providing GMP viral vectors from early stage to market.
